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Abstract
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a congenital storage disorder resulting from mutations on the iduronate-2-
sulfatase (IDS) gene. The disease shows variable clinical phenotypes from severe to mild with progressive neurological dysfunction. The
therapeutic options for treatment of MPS II are limited and currently no specific therapies are available; the problem is further compounded
by difficulties in delivering therapeutic agents to the central nervous system (CNS). In this work, as a potential treatment for this disease, the
transfer of the recombinant IDS enzyme into brain cells has been studied in vitro. Two different approaches to obtain recombinant IDS have
been utilized: production of the recombinant enzyme by a transfected human clone (Bosc 23 cells); production of the recombinant enzyme by
adenoviral transduction of neuronal (SK-N-BE) or glial (C6) cells. Our data indicate that the transfected as well as the infected cells produce a
large amount of the IDS enzyme, which is efficiently endocytosed into neuronal and glial cells through the mannose 6-phosphate (M6P)
receptor system. Somatic gene therapy appears therefore to be suitable to correct IDS deficiency in brain cells.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Iduronate-2-sulfatase (IDS; E.C. 3.1.6.13) is a lysosomal
enzyme involved in the catabolism of the mucopolysacchar-
ides heparan and dermatan sulfate. In humans, the inherited
deficiency of this enzymatic activity results in mucopoly-
saccharidosis type II (MPS II, Hunter syndrome) (for
review, see Ref. [1]). Patients accumulate undegraded der-
matan and heparan sulfate in the lysosomes of most cell
types and this accumulation, particularly within cells of the
neurological system, leads to a wide spectrum of clinical
phenotypes, ranging from the mild form with late onset and
absent or moderate mental retardation to the severe form
characterized by progressive somatic and neurologic
involvement. The 24-kb IDS gene is located on the Xq27/
28 boundary and the 2.3-kb cDNA encodes a protein of 550
amino acids [2–4]. The IDS protein is synthesized as two
precursor forms of 90 and 76 kDa; subsequent modification
of N-linked sugar residues, with the addition of mannose 6-
phosphate (M6P), targets newly synthesized IDS to lysoso-
mal compartments where, after a proteolytic cleavage, it is
converted into a 45- to 42-kDa mature polypeptide [5,6].
The cloning of IDS cDNA sequences has allowed the
identification of a large variety of IDS locus alterations
(for reviews, see Refs. [7,8]) with subsequent genotype/
phenotype correlation for many of the described mutations.
Moreover, some IDS mutant proteins have been character-
ized in expression studies [9–12].
Lysosomal enzymes are post-translationally processed to
contain phosphorylated M6P residues. These bind to M6P
receptors which target proteins to the lysosomes. Receptors
are also present on the cell membrane and are able to bind
circulating or extracellular lysosomal enzymes and deliver
them to the lysosomes (for review, see Ref. [13]). Thus,
enzyme replacement has been suggested for the treatment of
lysosomal storage diseases. Despite substantial clinical and
laboratory experimentation for the treatment of these disor-
ders in which there is significant neurological involvement,
little is known about the capacity of neuronal and glial cells
to take up individual lysosomal enzymes from the extrac-
ellular medium and process them correctly within the lyso-
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somes. Little research has been carried out to this regard; it
has been reported that neurons and glial cells contain the
appropriate M6P receptors necessary to take up all lysosomal
enzymes from the extracellular medium and that extracellu-
lar a-L-iduronidase is indeed endocytosed [14]; moreover, it
has been reported that a high percentage of M6P glycopro-
teins are present in rat brain [15]. However, no experiments
have been done to assess the capacity of neuronal and glial
cells, in vitro, to correctly process endocytosed lysosomal
proteins. Thus, our aim was to extend these in vitro studies to
the IDS enzyme; our experiments were designed to assess
whether neuronal and glial cells could take up recombinant
IDS from the extracellular medium, retain it intracellularly
and process it correctly within the lysosomes. Two sources of
recombinant IDS have been used: (1) enzyme secreted by
transfected human Bosc 23 cells and (2) enzyme secreted by
adenovirally transduced neuronal and glial cells, since the
capacity of the recombinant vector AdRSVIDS to transduce
human normal and Hunter fibroblasts has been previously
demonstrated [16].
2. Materials and methods
2.1. Cell cultures
Bosc 23 (human kidney cells) were grown in Dulbecco’s
modified Eagle medium (DMEM). SK-N-BE (human neu-
roblastoma) and C6 (rat glioma) cell lines were grown in
monolayers in RPMI 1640. All media were supplemented
with 10% FCS, 100 U/ml penicillin, 100 Ag/ml streptomy-
cin, 2 mM L-glutamin (all purchased from Life Technolo-
gies, Italy). Cells were grown at 37 jC in a 5% CO2/air
atmosphere. SK-N-BE cells were treated with 5 AM trans
retinoic acid (RA) (Sigma) for 3 days to induce differ-
entiation [17].
2.2. Bosc 23 cells transfection
Ten micrograms of the plasmid pCXN [18] containing
the IDS cDNA was introduced into Bosc 23 cells by
electroporation using a BioRad Gene Pulser apparatus and
a pulse of 250 V/960 AF. The cells were grown in non-
selective medium for 48 h and then subcultured into
medium containing 0.375 mg of active Geneticin (G418)/
ml. After 2 weeks selection, G418-resistant colonies were
harvested by tripsinisation, expanded in DMEM/G418,
cloned in flat-bottomed 96-well tissue plates by limiting
dilution, and assayed for IDS activity.
2.3. Adenovirus infection
The virus AdRSVIDS, previously described [16], carries
in the E1 region of its genome the IDS cDNA driven by the
RSV promoter. It was generated, purified and titred accord-
ing to standard techniques [19].
RA-treated SK-N-BE neuronal cells and C6 glial cells
were grown in 60-mm plates and infected with 20 or 50 pfu/
cell of AdRSVIDS. The day before the infection, both cell
lines were seeded; one additional plate of each line was
seeded for counting. The next day, cells were counted just
before the infection which was performed for 30 min at 37
jC in PBS+ + containing an amount of virus dependent on
the cell number and on the multiplicity of infection chosen.
Mock samples were instead treated with PBS+ + alone. All
cells were afterwards refed and harvested 48 h later.
To assess the efficiency of adenovirus infection in both
SK-N-BE and C6 cell lines, a control virus, AdHCMVS-
p1lacZ [20] expressing the E. coli lacZ reporter gene, was
used, at 10-20-50-100 pfu/cell. X-gal staining, performed 48
h post-infection showed for both cell lines an efficiency of
infection around 100% already at 50 pfu/cell, which was
therefore taken as the maximum multiplicity to be used in
the following experiments.
2.4. Enzyme analysis
Cell pellets were washed twice with 150 mM NaCl,
resuspended in the same buffer and frozen–thawed six
times. The protein content was determined in cell lysates
according to Lowry et al. [21]. The IDS assay was per-
formed as described: 2 Ag of cellular proteins was incubated
with 20 Al of the substrate 4-methylumbelliferyl-a-iduro-
nide-2-sulfate (MU-aIdu-2S) and kept for 4 h at 37 jC, after
which 10 Al of RLC (Rabbit Liver ConA fraction) was
added and the reaction continued for 24 h more. The
reaction was terminated by adding the appropriate stop
buffer and the amount of product obtained was evaluated
using a fluorometer with 365 nm excitation and 446
emission [22].
2.5. Endocytosis of recombinant IDS produced by stably
transfected Bosc 23 cells into SK-N-BE neuronal and C6
glial cells. Effect of M6P
IDS Bosc 23 cell clones were grown to 70% confluency
in 60-mm plates, after which fresh medium was added and
left for 24 h, then removed and clarified by centrifugation at
200 g for 5 min. The conditioned medium was then trans-
ferred onto recipient cells (RA-treated SK-N-BE cells or C6
cells) and cultures incubated for 2 days in the absence or in
the presence of M6P. After 48 h endocytosis, the cells were
trypsinized and the IDS activity measured in cell extracts.
In another set of experiments, IDS Bosc 23 cell clones
were labeled for 2 h (pulse) with 35S-Express Protein
Labeling Mix; medium was changed and left for 24 h chase
period. Chase medium was removed, clarified by centrifu-
gation as described and added to SK-N-BE or C6 cells in the
absence or in the presence of 5 mM M6P. After 48 h
endocytosis, the cells were washed with PBS, lysed on ice
for 30 min in 500 Al lysis buffer (10 mM EDTA pH 8, 0.1%
Triton X-100, 0.2 mM PMSF, 1 mM pepstatin A and 1 mM
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leupeptin) and centrifuged for 15 min at 13600 g. Radio-
labeled supernatants were treated overnight with 1 Al anti-
IDS antiserum. Immune complexes were precipitated with
30 Al protein A-Agarose (Santa Cruz Biotechnology) for 1 h
at 4 jC, washed four times with lysis buffer, analyzed by
SDS-PAGE followed by fluorography.
2.6. Endocytosis of recombinant IDS produced by AdRS-
VIDS infected SK-N-BE and C6 cells into a second
population of neuronal and glial cells. Effect of M6P
RA-treated SK-N-BE cells and C6 glial cells were grown
to 70% confluency in 60-mm plates and were infected with
50 pfu/cell of AdRSVIDS; after 48 h, the medium was
removed and clarified by centrifugation as described. The
conditioned medium was then transferred onto recipient
cells (a second population of untreated SK-N-BE or C6
cells) and cultures incubated for 2 days in the absence or in
the presence of 5 mM M6P. After 48 h endocytosis, the cells
were trypsinized and the IDS activity was measured in the
cell extracts.
In another set of experiments, infected SK-N-BE and C6
cells were labeled for 2 h (pulse) with 35S-Express Protein
Labeling Mix; the medium was changed and left for 24 h
chase period. The conditioned labeled medium was
removed, clarified and added to a second population of
untreated SK-N-BE or C6 cells in the absence or in the
presence of 5 mM M6P. After 48 h endocytosis, the cells
were treated exactly as described in Section 2.5.
3. Results
3.1. Generation of clonal cell lines expressing IDS
The pCXN expression vector containing the full-length
cDNA for IDS was electroporated into Bosc 23 cells and
stable clones selected using 0.375 mg of active Geneticin
(G418)/ml; 24 clones were isolated and assessed for the
level of IDS activity. Enzyme levels were between 205.3
and 496.0 nmol/4 h/mg. Clones C7, C10 and C18 showed
the highest levels of IDS activity (Table 1), clone C10
resulting the best for IDS expression in the cells (4.5-fold
the level of untreated cells) and in the medium (3.3-fold the
level of untreated cells) (Table 1); it was therefore used for
the production of recombinant IDS enzyme.
3.2. Endocytosis of recombinant IDS enzyme produced by
stably transfected Bosc 23 cells into SK-N-BE and C6 cells.
Evaluation of enzyme activity
To characterize the process by which neuronal SK-N-BE
and C6 glial cells can acquire the lysosomal IDS enzyme,
we performed an uptake cross-correction experiment to
demonstrate active endocytosis. The basal levels of IDS in
RA-treated SK-N-BE cells and C6 cells were 19.2 and 23.2
nmol/4 h/mg, respectively. To study neuronal uptake, the
conditioned medium from C10 clone was used as a source
of IDS for in vitro cultured SK-N-BE and C6 cells. Internal-
ization of IDS was monitored after 48 h endocytosis: a
significant increase in the enzyme activity was detected
intracellularly in SK-N-BE (358.3%) and in C6 cells (379%)
(Table 2). When the experiment was performed in the
presence of 5 mM M6P, the IDS activity levels were similar
to the basal levels (Table 2), indicating that endocytosis of
IDS was mediated by the M6P receptor pathway. Taking
into account the total enzyme units (35) measured in the
extracellular medium and the total enzyme units (1.7 and
2.2) recovered in the recipient cells (SK-N-BE and C6,
respectively), a mean value of 5.6% endocytosis was calcu-
lated.
3.3. Endocytosis of recombinant IDS enzyme produced by
stably transfected Bosc 23 into SK-N-BE and C6 cells.
Evaluation of enzyme maturation
To study the maturation of the IDS protein after endocy-
tosis into SK-N-BE and C6 cells, the medium of the C10
clone, containing the labeled precursor forms of IDS, was
added to SK-N-BE and C6 cells, in the absence or in the
presence of M6P. The results are shown in Fig. 1; the
precursor 76-kDa form in the absence of M6P was efficiently
endocytosed, resulting in both cell types in the mature form of
43 kDa. The presence of 5 mM M6P again inhibited the
uptake of the enzyme.
Table 1
IDS activity measured in three isolated clones of Bosc 23 cells after stable
transfection with expression vector pCXN. Transfected cells were selected
in G418
Bosc-23 Cells (nmol/4 h/mg) Medium (nmol/4 h/ml)
Untransfected 108.5F 12.3 1.2F 0.3
C7-clone 336.1F 23.2 2.2F 0.5
C10-clone 496.0F 4.1 4.0F 1.1
C18-clone 393.2F 29.6 2.7F 1.2
IDS activity is given as nmol/4 h/mg and represents the meanF S.D. of
triplicate 60-mm plates.
Table 2
Endocytosis of recombinant IDS from Bosc 23 cells into SK-N-BE





Control cells (meansF S.D.) 19.2F 0.15 23.2F 1.15
Cells + conditioned media
(meansF S.D.)
69F 9.8 88F 10.4
Percentage versus controls 358 379
Cells + conditioned media +M6P
(meansF S.D.)
23.2F 1.3 26.4F 2.1
SK-N-BE andC6 cells were treated for 2 dayswith conditionedmedium from
Bosc 23 cells in the absence or in the presence of 5 mM M6P. Control cells
were maintained in unconditioned medium for the same time. IDS levels are
given as nmol/4 h/mg and represent the meanF S.D. of triplicate plates.
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3.4. Adenovirus infection of SK-N-BE neuronal and C6 glial
cells
Triplicate 60-mm plates of neuronal SK-N-BE and C6
glial cells were infected with the viral vector AdRSVIDS at
20 and 50 pfu/cell, as described in Materials and Methods
and the IDS activity was tested 48 h after infection. An IDS
basal activity of 24 and 29 nmol/4 h/mg was observed in
untreated SK-N-BE and C6 cells, respectively (Table 3);
after infection with 20 pfu, an IDS increase above the basal
level of 9.2-fold (intracellular) and 4.4-fold (extracellular)
was found in SK-N-BE cells, while an increase of 8.5-fold
(intracellular) and 7.1-fold (extracellular) was observed in
C6 cells (Table 3). Infection with 50 pfu resulted in higher
increases in the IDS activity: 18.1-fold and 10.6-fold in SK-
N-BE (cells and medium, respectively); 16-fold and 15.6-
fold in C6 (cells and medium, respectively) (Table 3).
3.5. Endocytosis of recombinant IDS enzyme produced by
AdRSVIDS infected SK-N-BE and C6 cells into a second
population of untreated cells. Evaluation of enzyme activity
To evaluate whether the enzyme secreted from trans-
duced neuronal SK-N-BE and C6 glial cells could be
taken up by a second population of untreated cells, the
conditioned medium from transduced cells was added to
uninfected neuronal and glial cells. After 48 h, the target
cells were tested for IDS activity. The results are shown
in Table 4: the SK-N-BE cells, with a basal activity of
24.7 nmol/h/mg, after 48 h incubation with conditioned
medium showed an activity of 334 nmol/4 h/mg, namely
an increase of 1352%; the C6 cells, with a basal activity
of 30.4 nmol/h/mg, after 48 h incubation with a condi-
tioned medium showed an activity of 436 nmol/4 h/mg,
namely an increase of 1434%. The presence of 5 mM
M6P in the system blocked the IDS uptake (Table 4).
Taking into account the total enzyme units (12.0 and
14.1) measured in the extracellular medium of SK-N-BE
and C6, respectively, and the total enzyme units (8.8 and
10.5) recovered in the recipient cells, a mean value of
74% endocytosis was calculated.
Table 3
IDS activity in SK-N-BE neuronal cells and C6 glial cells after adenoviral infection








Control cells (untreated) 24F 2.4 1.13F 0.9 29F 3.5 0.9F 0.4
Infected cells (20 pfu) 221F 31.8 4.97F 2.1 246F 56.2 6.41F 2.6
Infected cells (50 pfu) 434F 83.1 12.0F 3.5 465F 75.5 14.1F 4.5
IDS activity, determined 48 h after infection, represents the meanF S.D. of triplicate plates.
Fig. 1. Endocytosis of IDS produced by Bosc 23 cells into SK-N-BE
neuronal and C6 glial cells. Effect of M6P. Bosc 23 cells, stably transfected
with IDS cDNA construct, were labeled for 2 h (pulse) with 35S-Express
Protein Labeling Mix. After a subsequent period of 24 h (chase), the media,
containing the precursor forms of the enzymes, were collected and
concentrated to 0.5 ml by Millipore Centricon Centrifugal Filter Device or
were directly added to RA-treated SK-N-BE and to C6 cells in the absence
() or presence (+) of 5 mM M6P for 48 h endocytosis. IDS protein was
immunoprecipitated from concentrated Bosc 23 medium or from
homogenates of target cells, separated by SDS-PAGE and detected by
fluorography. The mass (in kilodaltons) of the molecular weight markers is
indicated on the left. M, medium; C, cell lysate. The arrows on the right
indicate the 76-kDa precursor form and the 43-kDa mature IDS form.
Table 4
Endocytosis of recombinant IDS from AdRSVIDS infected SK-N-BE






Control cells (meansF S.D.) 24.7F 2.4 30.4F 3.6
Cells + conditioned media
(meansF S.D.)
334F 42.1 435.9F 50.3
Percentage versus controls 1352.2 1433.8
Cells + conditioned media +M6P
(meansF S.D.)
107F 25.6 112F 31.9
SK-N-BE and C6 cells were cultured for 48 h in conditioned medium from
AdRSVIDS infected cells in the absence or in the presence of 5 mM M6P.
Control cells for each cell type were maintained in unconditioned medium
for the same time. IDS levels are given as nmol/4 h/mg and represent the
meanF S.D. of triplicate plates.
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3.6. Endocytosis of recombinant IDS enzyme produced by
AdRSVIDS infected SK-N-BE and C6 cells into a second
population of untreated neuronal and glial cells. Evaluation
of enzyme maturation
Immunoprecipitation experiments were performed to
confirm the internalization of the IDS protein in untreated
SK-N-BE and C6 cells. To this purpose, the conditioned
medium by SK-N-BE and C6 was added to the same cells,
in the absence or in the presence of M6P. The results are
shown in Fig. 2; the recombinant IDS protein secreted into
the culture medium was taken up by recipient cells and
correctly processed to the mature form of 45 kDa. The
presence of 5 mM M6P inhibited the uptake of the enzyme.
It should be noted that, in contrast with the results shown in
Fig. 1, the attempt to immunoprecipitate the precursor form
in the conditioned medium of SK-N-BE and C6 cells was
unsuccessful. Apparently, this precursor form obtained in
neuronal cells after adenovirus infection contains some
difference(s) with respect to the precursor form found after
Bosc 23 transfection. A similar problem was encountered
with the IDS protein expressed in another cell type [12].
4. Discussion
MPS II is a storage disorder with multiple sites of
pathology, including the central nervous system (CNS).
Currently, only symptomatic treatments are available; only
a few patients, without severe neuropsychological impair-
ment, have undergone bone marrow transplantation [23–
25]. At present, MPS II is considered to be a candidate
disorder for enzyme replacement therapy (ERT) and for
gene therapy. In this respect, the in vitro correction of
Hunter fibroblasts or lymphocytes [16,26–28] and in vivo
autologous transplantation of genetically corrected periph-
eral blood lymphocytes [29] are currently the only options
available to accomplish gene delivery of the correct gene
sequence. However, the in vivo experiments on the CNS
have been disappointing due to the blood-brain barrier and
the in vitro experiments on CNS cells have never been
performed, indicating the need for further investigation.
In this study, we have generated human kidney cells,
Bosc 23, which overexpress and secrete human IDS follow-
ing stable transfection with the IDS pCXN expression
vector. After transfection, the IDS activity increased both
in the cells and in the culture medium. The recombinant
Bosc 23 cells were used as donor cells for in vitro cell-
mediated enzyme replacement of neuronal SK-N-BE and
C6 glial cells. We have demonstrated that the recombinant
IDS enzyme produced by transfected Bosc 23 cells was
efficiently taken up by neuronal and glial cells through the
M6P receptor pathway. Metabolic labeling experiments
have confirmed the enzymatic data demonstrating that the
recombinant protein was not only properly glycosylated for
uptake but also correctly processed into the brain cells in the
mature form of 45–42 kDa.
At the same time, we have demonstrated that the repli-
cation defective adenovirus vector AdRSVIDS can be
efficiently transduced into neuronal SK-N-BE and C6 cells;
after infection, the enzymatic activity increased both intra-
cellularly and in the extracellular medium. Furthermore, the
experiments of metabolic labeling showed that the recombi-
nant IDS enzyme, produced in neuronal and glial cells by
the AdRSVIDS adenovirus vector, was endocytosed by a
second population of the untreated cells and underwent
correct processing to the 45–42-kDa mature form.
Previously, in vitro studies have shown that recombinant
lysosomal enzymes, including IDS, are correctly localized
in lysosomes of the transduced cells and normalize the
substrate catabolism [14,16,26,27,30]; other studies on
recombinant lysosomal proteins have indicated that these
enzymes are properly glycosylated for uptake [14,26].
Recent data suggest that enzyme preparations containing
phosphorylated h-glucuronidase are more effective than the
non-phosphorylated enzyme in the clinical response to ERT
in MPS VII mice [31]; on the other hand, overexpression
resulting in intracellular aggregation may interfere with
intracellular trafficking and optimal substrate degradation
[32].
Fig. 2. Endocytosis of IDS produced by transduced SK-N-BE neuronal and
C6 glial cells into a second population of untreated recipient cells. Effect of
M6P. RA-treated SK-N-BE and C6 cells were infected with AdRSVIDS at
20 pfu/cell; 18 h later, the cells were labeled for 2 h (pulse) with 35S-
Express Protein Labeling Mix. After a subsequent period of 24 h (chase),
the media, containing the precursor forms of the enzymes, were added to
untreated SK-N-BE and C6 cells in the absence () or presence (+) of 5
mM M6P. After 48 h of endocytosis, IDS protein was immunoprecipitated
from homogenates of target cells, separated by SDS-PAGE and detected by
fluorography. The mass (in kilodaltons) of the molecular weight markers is
indicated on the left. The arrow on the right indicates the 45-kDa mature
IDS form.
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In conclusion, we have demonstrated that cultured CNS
cells can be efficiently induced to produce or endocytose
therapeutic levels of recombinant IDS enzyme and that the
recombinant protein is subsequently correctly processed
within the lysosomes. These results may have important
implications both for enzyme replacement therapy and for
gene therapy for neurological disorder of MPS II. In view of
the considerable problem of the blood-brain barrier, a
potential therapeutic approach could be based on intrathecal
treatment of the recently obtained MPS II mouse model
[33].
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